Manik Kuvalekar

Jan 7, 2025 | digitalcommons.library.tmc.edu | Valentina Hoyos |Spyridoula Vasileiou |Manik Kuvalekar |Ayumi Watanabe

PURPOSE: Adoptively transferred, ex vivo expanded multi-antigen-targeted T cells (multiTAA-T) represent a new, potentially effective, and nontoxic therapeutic approach for patients with breast cancer (BC). In this first-in-human trial, we investigated the safety and clinical effects of administering multiTAA T cells targeting the tumor-expressed antigens, Survivin, NY-ESO-1, MAGE-A4, SSX2, and PRAME, to patients with relapsed/refractory/metastatic BC.